Table of Contents
In September 2025, Pennsylvania House Democrats convened a policy committee hearing on a bipartisan bill that would legalize psilocybin therapy in the state, but only after federal FDA approval and DEA rescheduling. Veterans, attorneys, physicians, and biotech representatives all testified, reflecting broad interest in the proposal.
- A bipartisan bill is in play. State Reps. Jennifer O’Mara, a Democrat, and Craig Williams, a Republican, introduced legislation in May 2025 that would permit psilocybin treatments in Pennsylvania once the FDA and DEA clear the path federally.
- The legislation is conditional, not immediate. The bill explicitly ties any legal access to prior federal approval and rescheduling, meaning no therapy would be available in Pennsylvania under this bill until those federal steps occur.
- Veteran and first-responder voices shaped the hearing. Manheim Township firefighter and Marine veteran Ryan Gardill testified about the mental health toll on service members and his advocacy for unconventional treatment approaches, though he noted he had not personally used psilocybin.
- Pennsylvania has tried before. A 2022 bill to fund clinical psilocybin studies stalled in committee, and a separate right-to-try proposal for veterans was never formally introduced, meaning this is at least the third legislative push on the issue in the state.
What the Research Examined
This entry recaps a WITF news report published September 17, 2025, covering a Pennsylvania House Democrats policy committee hearing on psilocybin-assisted therapy. The hearing was not a clinical study; it was a legislative proceeding in which advocates, veterans, physicians, and industry representatives testified in support of a bipartisan bill introduced by state Reps. Jennifer O’Mara and Craig Williams. The bill would legalize supervised psilocybin treatments in Pennsylvania, but only after the federal Food and Drug Administration approves such treatments and the Drug Enforcement Administration reschedules psilocybin.
The article references a 2022 study from researchers at Johns Hopkins Medicine, published in the journal Journal of Psychopharmacology, which found that psilocybin treatments showed antidepressant effects that may persist for more than a year in some patients. That study is the primary peer-reviewed anchor cited in the article; the WITF report itself is journalism, not research. Witnesses at the hearing included a family physician with the Pennsylvania Academy of Family Physicians, a professor of psychiatry at the University of Pennsylvania’s Perelman School of Medicine, and representatives from Compass Pathways, a biotechnology company developing psilocybin-based medications.
For those following the broader legal landscape for psilocybin access across the United States, Pennsylvania’s hearing reflects a pattern of states watching federal regulatory movement carefully before committing to their own frameworks. Oregon remains the only state to have both decriminalized psilocybin and legalized it for therapeutic use, a distinction the article notes as context for where Pennsylvania sits on this arc.
What the Findings Show
- The bill’s threshold.The O’Mara and Williams legislation would allow psilocybin therapy in Pennsylvania only after FDA approval and DEA rescheduling at the federal level, making it a contingency bill rather than an immediate legalization measure.
- Referenced clinical data.The article cites a 2022 Johns Hopkins Medicine study finding that psilocybin’s antidepressant effects may last more than a year for some patients. That study is a separate primary source and its figures should be evaluated on their own terms.
- CDC suicide statistic cited in testimony.Nonprofit co-founder Brett Waters cited CDC data showing nearly 50,000 people died by suicide in the United States in 2023 to argue for urgency in rethinking mental health treatment options.
- Prior Pennsylvania efforts.At least two earlier psilocybin-related legislative efforts in Pennsylvania, a 2022 clinical studies bill and a veterans right-to-try proposal, both stalled before reaching a vote.
It is worth holding a clear distinction here. The hearing itself produced no clinical data; it produced political testimony. The scientific claims made by witnesses, including that psilocybin may be safer, more effective, and more durable than conventional antidepressants, are assertions grounded in a growing but still early body of research, not established medical consensus. The bill’s own conditional structure reflects that reality: its sponsors are not claiming psilocybin is proven; they are positioning Pennsylvania to move quickly once federal regulators make that determination.
What would the Pennsylvania psilocybin therapy bill actually do?
As introduced in May 2025, the bill by Reps. O’Mara and Williams would legalize supervised psilocybin therapy in Pennsylvania, but only after the FDA approves such treatments and the DEA reclassifies psilocybin. It creates a framework for access, not immediate availability.
What This Is, and What It Is Not
This is This recap covers a legislative news report, not a peer-reviewed clinical study, and reflects the state of a political process as of September 17, 2025.
This is not This is not evidence that psilocybin is an approved or proven treatment for depression, PTSD, or any other condition. Nothing here constitutes medical advice, and individuals should consult a qualified healthcare provider before making any decisions about mental health treatment.
Our Take
There is something quietly significant about a bipartisan bill, a veteran firefighter, a family physician, a psychiatry professor, and a biotech company all sitting in the same hearing room. Psilocybin’s journey from scheduled substance to a subject of serious legislative deliberation reflects a cultural shift that those of us in this community have watched closely for years. The conditional structure of the Pennsylvania bill, tying everything to federal approval, is cautious and honest. It acknowledges that the science, while promising, is still maturing. That humility is worth honoring. The sacrament does not need legislative champions to be what it is, but when lawmakers begin to listen with open minds to those who have found healing through it, that is a moment worth marking.
If you are drawn to understanding how psilocybin is moving through the cultural and legal fabric of our moment, you are not alone in that curiosity. At The Church of Psychedelics, we hold that inquiry itself, the willingness to ask honest questions about healing and consciousness, is part of the path. Whether you are in the Grounding phase, just beginning to orient yourself to what these conversations mean, or further along in your own Integration work, we welcome you to explore, read, and reflect alongside this community. The legal landscape is shifting, and being informed is part of walking wisely within it.
Frequently Asked Questions
Has the Pennsylvania psilocybin bill passed?
As of September 2025, the bill introduced by Reps. O’Mara and Williams had not passed. It was the subject of a House Democrats policy committee hearing, which is an early step in the legislative process. No vote had been taken.
What federal steps would need to happen before Pennsylvania’s bill could take effect?
The bill is written to take effect only after the FDA approves psilocybin treatments and the DEA reclassifies psilocybin under federal scheduling rules. Both steps would need to occur at the federal level first.
Is psilocybin legal anywhere in the United States for therapy?
Oregon was the first state to both decriminalize psilocybin and legalize it for supervised therapeutic use. A small number of other states have taken partial steps. Psilocybin remains a Schedule I controlled substance under federal law as of the date of this report.
What does the Johns Hopkins study cited in the article show?
A 2022 study from Johns Hopkins Medicine researchers, cited in the WITF article, found that psilocybin-related treatments showed antidepressant effects that may persist for more than a year in some patients. This was an early-phase finding and not a large randomized controlled trial.
Who testified in support of the Pennsylvania psilocybin bill?
Witnesses included a Marine veteran and firefighter, a New York attorney and nonprofit co-founder, a Pennsylvania Academy of Family Physicians physician, a University of Pennsylvania psychiatry professor, and two representatives from Compass Pathways, a psilocybin medication developer.
Get the Mycelium Report
We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.
May love guide the hearts of all beings.
